Clinical Trial Diversity Efforts Look Beyond COVID-19

Genentech Enlists Trial Sites In Oncology Initiative

At The Atlantic’s Health Equity Summit, panel discussions highlighted efforts to improve diversity in clinical trials of diseases like lupus, which disproportionately affects women of color.

Closed up finger on keyboard with word CLINICAL TRIALS
Panel discussions at a recent summit highlighted clinical trial diversity efforts in areas like cancers and lupus • Source: Shutterstock

The COVID-19 pandemic drew renewed attention to the issue of clinical trial diversity, but discussion of the issue at The Atlantic’s Health Equity Summit on 22 June highlighted how the focus has begun to shift from the pandemic to other disease areas, including oncology and rheumatology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diversity & Inclusion

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

More from ESG

Why Global Pull Incentives Matter For AMR Drugs

 
• By 

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.